(Q34469287)

2 August 2017

1 reference

title

Pharmacokinetic, Pharmacodynamic, and Drug-Interaction Profile of the Hepatitis C Virus NS5B Polymerase Inhibitor Sofosbuvir (English)

1 reference

2 August 2017

0 references

1 reference

1 reference

1 reference

1 reference

Brian J Kirby

1

1 reference

2 August 2017

William T Symonds

series ordinal

2

1 reference

2 August 2017

Brian P Kearney

series ordinal

3

1 reference

2 August 2017

Anita A Mathias

series ordinal

4

1 reference

2 August 2017

1 July 2015

1 reference

Clinical Pharmacokinetics

2 August 2017

1 reference

2 August 2017

54

1 reference

2 August 2017

7

1 reference

2 August 2017

677-690

1 reference

https://scigraph.springernature.com/pub.10.1007/s40262-015-0261-7

2 August 2017

0 references

cites work

Sofosbuvir and ribavirin for hepatitis C in patients with HIV coinfection

1 reference

12 December 2020

Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation

1 reference

12 December 2020

Sofosbuvir for previously untreated chronic hepatitis C infection

1 reference

12 December 2020

Fluvoxamine and fluoxetine do not interact in the same way with the metabolism of the enantiomers of methadone.

1 reference

12 December 2020

Pharmacokinetics and bioavailability of an integrase and novel pharmacoenhancer-containing single-tablet fixed-dose combination regimen for the treatment of HIV.

1 reference

12 December 2020

Relationship of liver disease stage and antiviral therapy with liver-related events and death in adults coinfected with HIV/HCV

1 reference

12 December 2020

Viral hepatitis and HIV co-infection

1 reference

12 December 2020

A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability

1 reference

12 December 2020

Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options

1 reference

12 December 2020

Pharmacokinetics, pharmacodynamics, and tolerability of GS-9851, a nucleotide analog polymerase inhibitor, following multiple ascending doses in patients with chronic hepatitis C infection

1 reference

12 December 2020

Binding of d-methadone, l-methadone, and dl-methadone to proteins in plasma of healthy volunteers: role of the variants of alpha 1-acid glycoprotein

1 reference

12 December 2020

Hepatic but not intestinal CYP3A4 displays dose-dependent induction by efavirenz in humans

1 reference

12 December 2020

Effect of tipranavir-ritonavir on pharmacokinetics of raltegravir

1 reference

12 December 2020

Sofosbuvir and ribavirin in HCV genotypes 2 and 3.

1 reference

12 December 2020

Minimal effects of ritonavir and efavirenz on the pharmacokinetics of raltegravir

1 reference

12 December 2020

Effects of human immunodeficiency virus protease inhibitors on the intestinal absorption of tenofovir disoproxil fumarate in vitro.

1 reference

12 December 2020

Sofosbuvir (GS-7977) plus peginterferon/ribavirin in treatment-naïve patients with HCV genotype 1: a randomized, 28-day, dose-ranging trial

1 reference

12 December 2020

Mechanism of activation of PSI-7851 and its diastereoisomer PSI-7977

1 reference

12 December 2020

Integrated internist - addiction medicine - hepatology model for hepatitis C management for individuals on methadone maintenance

1 reference

12 December 2020

Pharmacokinetics and pharmacodynamics of methadone enantiomers after a single oral dose of racemate.

1 reference

12 December 2020

10.1007/S40262-015-0261-7

Identifiers

DOI

1 reference

Dimensions Publication ID

2 August 2017

0 references

1 reference